<DOC>
	<DOCNO>NCT00265239</DOCNO>
	<brief_summary>Early reperfusion therapy improve clinical outcome patient acute myocardial infarction ( AMI ) , benefit limit patient reperfusion injury . There increase evidence reactive oxygen specie cause reperfusion injury . This study design examine effect edaravone , novel free radical scavenger , patient AMI .</brief_summary>
	<brief_title>Pilot Study Edaravone Treat Acute Myocardial Infarction</brief_title>
	<detailed_description>Initial AMI patient randomly assign receive 30 mg edaravone placebo intravenously reperfusion . We compare infarct size , use serial determination serum biomarkers Q wave formation , incidence reperfusion arrhythmia group . Cardiovascular event-free curve estimate Kaplan-Meier method . In addition , determine serum thioredoxin level , oxidative stress marker , ass antioxidant effect edaravone .</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Reperfusion Injury</mesh_term>
	<mesh_term>Phenylmethylpyrazolone</mesh_term>
	<mesh_term>Antipyrine</mesh_term>
	<criteria>Initial AMI patient admit investigator ' institution within 6 hour symptom onset treat primary percutaneous coronary intervention . Renal insufficiency define serum creatinine &gt; 1.2 mg/dl alter hepatic function define serum asparate aminotransferase &gt; 50 IU/L , alanine aminotransferase &gt; 50 IU/L total bilirubin &gt; 1.2 mg/dl .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2007</verification_date>
	<keyword>Edaravone</keyword>
	<keyword>Randomized Control Trial</keyword>
	<keyword>ST-Elevation Myocardial Infarction</keyword>
	<keyword>Coronary Angioplasty</keyword>
</DOC>